The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients.


Journal

British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544

Informations de publication

Date de publication:
07 2019
Historique:
received: 02 01 2019
accepted: 06 02 2019
pubmed: 28 3 2019
medline: 27 5 2020
entrez: 28 3 2019
Statut: ppublish

Résumé

The prognostic significance of low-hypodiploidy has not been extensively evaluated in minimal residual disease (MRD)-oriented protocols for adult acute lymphoblastic leukaemia (ALL). We analysed the outcome of hypodiploid adult ALL patients treated within Programa Español de Tratamientos en Hematología (PETHEMA) protocols. The 5-year cumulative incidence of relapse (CIR) of low-hypodiploid B-cell precursor (BCP)-ALL was significantly higher than that of high-hypodiploids (52% vs. 12%, P = 0.013). Low-hypodiploid BCP-ALL patients aged ≤35 years showed superior survival (71% vs. 21%, P = 0.026) and lower 5-year CIR (17% vs. 66%, P = 0.090) than low-hypodiploids aged >35 years. Older adults and elderly low-hypodiploid BCP-ALL patients show dismal prognosis although achieving an end-induction good MRD response.

Identifiants

pubmed: 30916384
doi: 10.1111/bjh.15887
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

263-268

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Auteurs

Jordi Ribera (J)

Institut de Recerca contra la Leucemia Josep Carreras, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.

Isabel Granada (I)

Institut de Recerca contra la Leucemia Josep Carreras, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain.

Mireia Morgades (M)

Institut de Recerca contra la Leucemia Josep Carreras, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain.

Susana Vives (S)

Institut de Recerca contra la Leucemia Josep Carreras, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain.

Eulàlia Genescà (E)

Institut de Recerca contra la Leucemia Josep Carreras, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.

Celia González (C)

Institut de Recerca contra la Leucemia Josep Carreras, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.

Josep Nomdedeu (J)

Institut de Recerca contra la Leucemia Josep Carreras, Hospital Sant Pau, Barcelona, Spain.

Lourdes Escoda (L)

Institut Català d'Oncologia, Hospital Joan XXIII, Tarragona, Spain.

Pau Montesinos (P)

Hospital La Fe, Valencia, Spain.

Santiago Mercadal (S)

Institut Català d'Oncologia, Hospital Duran i Reynals, Hospitalet de Llobregat, Llobregat, Spain.

Rosa Coll (R)

Institut Català d'Oncologia, Hospital Josep Trueta, Girona, Spain.

José González-Campos (J)

Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Eugenia Abella (E)

Hospital del Mar, Barcelona, Spain.

Pere Barba (P)

Hospital Vall d'Hebron, Barcelona, Spain.

Arancha Bermúdez (A)

Hospital Marqués de Valdecilla, Santander, Spain.

Cristina Gil (C)

Hospital General de Alicante, Alicante, Spain.

Mar Tormo (M)

Hospital Clínico, Valencia, Spain.

María Pedreño (M)

Hospital Doctor Peset, Valencia, Spain.

Daniel Martínez-Carballeira (D)

Hospital Universitario Central de Asturias, Oviedo, Spain.

Jesús-María Hernández-Rivas (JM)

Hospital Universitario de Salamanca, Universidad de Salamanca, IBMCC (CSIC/USAL), IBSAL and CIBERONC, Salamanca, Spain.

Alberto Orfao (A)

Hospital Universitario de Salamanca, Universidad de Salamanca, IBMCC (CSIC/USAL), IBSAL and CIBERONC, Salamanca, Spain.

Joaquín Martínez-López (J)

Hospital Doce de Octubre, Madrid, Spain.

Jordi Esteve (J)

Institut de Recerca contra la Leucemia Josep Carreras, Hospital Clínic, Barcelona, Spain.

Pilar Bravo (P)

Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain.

Antoni Garcia-Guiñon (A)

Hospital Arnau de Vilanova, Lleida, Spain.

Guillermo Debén (G)

Hospital Juan Canalejo, A Coruña, Spain.

José M Moraleda (JM)

Hospital Clínico Universitario Virgen de la Arrixaca, IMIB, Universidad de Murcia, Murcia, Spain.

José A Queizán (JA)

Hospital General de Segovia, Segovia, Spain.

Xavier Ortín (X)

Hospital Verge de la Cinta, Tortosa, Spain.

María J Moreno (MJ)

Hospital Virgen de la Victoria, Málaga, Spain.

Evarist Feliu (E)

Institut de Recerca contra la Leucemia Josep Carreras, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain.

Francesc Solé (F)

Institut de Recerca contra la Leucemia Josep Carreras, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.

Josep M Ribera (JM)

Institut de Recerca contra la Leucemia Josep Carreras, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH